Evidence map›Paper›PMID 26686964›Full record

ArticleOphthalmology2016

Risk of Retinal Neovascularization in Cases of Uveitis.

Apurva K Patel, Craig W Newcomb, Teresa L Liesegang, Siddharth S Pujari, Eric B Suhler, Jennifer E Thorne, C Stephen Foster, Douglas A Jabs, Grace A Levy-Clarke, Robert B Nussenblatt and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. [DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2017
    Guideline
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Long-term success treating inflammatory epiretinal neovascularization with immunomodulatory therapy.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Optical coherence tomography angiography in uveitis.Journal of ophthalmic inflammation and infection · 2019
    Review
  19. [Pharmacological treatment strategies and surgical options for uveitis].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019
    Review
  20. Choroidal neovascularization post macular surgery: a case series.International journal of ophthalmology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 10 institutions in 3 countries.

Apurva K PatelOphthalmology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania; Retina Northwest P.C., Portland, Oregon.
Craig W NewcombBiostatistics and Epidemiology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania.
Teresa L LiesegangOphthalmology, Casey Eye Institute-Oregon Health Sciences University, Portland, Oregon.
Siddharth S PujariOm Eye Care Hospital, Belgaum, Karnataka, India; Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts.
Eric B SuhlerOphthalmology, Casey Eye Institute-Oregon Health Sciences University, Portland, Oregon; Portland Veterans Affairs Medical Center, Portland, Oregon.
Jennifer E ThorneOphthalmology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
C Stephen FosterMassachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts; Ophthalmology, Harvard Medical School, Boston, Massachusetts.
Douglas A JabsEpidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York; Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Grace A Levy-ClarkeDevers Eye Institute, Portland, Oregon; The Tampa Bay Uveitis Center, Safety Harbor, Florida.
Robert B NussenblattLaboratory of Immunology, National Eye Institute/National Institutes of Health, Bethesda, Maryland.
James T RosenbaumOphthalmology, Casey Eye Institute-Oregon Health Sciences University, Portland, Oregon; Internal Medicine, Casey Eye Institute-Oregon Health Sciences University, Portland, Oregon; Devers Eye Institute, Portland, Oregon.
H Nida SenLaboratory of Immunology, National Eye Institute/National Institutes of Health, Bethesda, Maryland.
Pichaporn ArtornsombudhOphthalmology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania; Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts; Division of Ophthalmology Somdech Phra Pinklao Hospital, Naval Medical Department, Royal Thai Navy, Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Srishti KothariOphthalmology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania; Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts.
John H KempenOphthalmology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania; Biostatistics and Epidemiology, University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania; Ocular Inflammation Service University of Pennsylvania/Scheie Eye Institute, Philadelphia, Pennsylvania. Electronic address: john.kempen@uphs.upenn.edu.
Systemic Immunosuppressive Therapy for Eye Diseases Research Group
Oregon Health & Science University · USMassachusetts Eye Research and Surgery Institute · USNational Eye Institute · USUniversity of Pennsylvania · USChulalongkorn University · THHarvard University · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USLegacy Health · USPenn Presbyterian Medical Center · US

Funding

Long-term Follow-up of the Systemic Immunosuppressive Therapy for Eye Diseases CohortR01EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2004 to 2025
$8.1M
Studies of Ocular inflammation: Clinical researchZIAEY000557 · NEI · NATIONAL EYE INSTITUTE · PI SEN, HATICE · 2017 to 2018
$2.0M
Complications of Immunosupression for Eye DiseasesR56EY014943 · NEI · UNIVERSITY OF PENNSYLVANIA · PI KEMPEN, JOHN H · 2009 to 2009
$159k
Intramural NIH HHSNEI NIH HHS EY014943NEI NIH HHS R01 EY014943NEI NIH HHS R56 EY014943
6 · The paper itself

Abstract

purposeTo evaluate the risk of and risk factors for retinal neovascularization (NV) in cases of uveitis.

designRetrospective cohort study.

participantsPatients with uveitis at 4 US academic ocular inflammation subspecialty practices.

methodsData were ascertained by standardized chart review. Prevalence data analysis used logistic regression. Incidence data analysis used survival analysis with time-updated covariates where appropriate.

main outcome measuresPrevalence and incidence of NV.

resultsAmong uveitic eyes of 8931 patients presenting for initial evaluation, 106 of 13,810 eyes had NV (prevalence = 0.77%, 95% confidence interval [CI], 0.60-0.90). Eighty-eight more eyes developed NV over 26,465 eye-years (incidence, 0.33%/eye-year; 95% CI, 0.27-0.41). Factors associated with incident NV include age <35 years compared with >35 years (adjusted hazard ratio [aHR], 2.4; 95% CI, 1.5-3.9), current cigarette smoking (aHR, 1.9; 95% CI, 1.1-3.4), and systemic lupus erythematosus (aHR, 3.5, 95% CI, 1.1-11). Recent diagnosis of uveitis was associated with an increased incidence of NV (compared with patients diagnosed >5 years ago, aHR, 2.4 [95% CI, 1.1-5.0] and aHR, 2.6 [95% CI, 1.2-6.0] for diagnosis within <1 year vs. 1-5 years, respectively). Compared with anterior uveitis, intermediate uveitis (aHR, 3.1; 95% CI, 1.5-6.6), posterior uveitis (aHR, 5.2; 95% CI, 2.5-11), and panuveitis (aHR, 4.3; 95% CI, 2.0-9.3) were associated with a similar degree of increased NV incidence. Active (aHR, 2.1, 95% CI, 1.2-3.7) and slightly active (aHR, 2.4, 95% CI, 1.3-4.4) inflammation were associated with an increased incidence of NV compared with inactive inflammation. Neovascularization incidence also was increased with retinal vascular occlusions (aHR, 10, 95% CI, 3.0-33), retinal vascular sheathing (aHR, 2.6, 95% CI, 1.4-4.9), and exudative retinal detachment (aHR, 4.1, 95% CI, 1.3-13). Diabetes mellitus was associated with a somewhat increased incidence of retinal NV (aHR, 2.3, 95% CI, 1.1-4.9), and systemic hypertension (aHR 1.5, 95% CI, 0.89-2.4) was associated with nonsignificantly increased NV incidence. Results were similar in sensitivity analyses excluding the small minority of patients with diabetes mellitus.

conclusionsRetinal NV is a rare complication of uveitis, which occurs more frequently in younger patients, smokers, and those with intermediate/posterior/panuveitis, systemic vasculopathy, retinal vascular disease, or active inflammation. Inflammation and retinal NV likely are linked; additional studies are needed to further elucidate this connection.

Indexed as

AdultCohort StudiesFemaleHumansIncidenceMaleMiddle AgedPrevalenceProportional Hazards ModelsRetinal NeovascularizationRetrospective StudiesRisk AssessmentRisk FactorsUnited StatesUveitis

Identifiers

PMID26686964
PMCPMC4766036
OpenAlexW2189826705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.